Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05766631
Other study ID # 11387
Secondary ID 1R01DA057608-01
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 26, 2023
Est. completion date September 29, 2027

Study information

Verified date September 2023
Source Friends Research Institute, Inc.
Contact Shannon G Mitchell, Ph.D.
Phone 410-837-3977
Email smitchell@friendsresearch.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to determine the effects of an app to reduce opioid and cocaine use when layered atop methadone treatment as usual among people using both opioids and cocaine. The main questions it aims to answer are: - Do people who use the app remain in methadone treatment longer than people who receive only treatment as usual? - Do people who use the app report using opioids and/or cocaine less often, and do they report better improvements in their quality of life, than people who receive only treatment as usual? - Does using the app more lead to better methadone treatment outcomes among people using the app? Participants in this study will be randomly assigned to receive either the app or methadone treatment as usual. Participants randomly assigned to the treatment as usual group will receive access to methadone services as normally provided, including scheduled access to medications, information about the consequences of opioid and other drug use, and any onsite services (including group based interventions and/or 12-step programs). Those randomized into the app-using group will receive all the same services as the treatment as usual group, but will also be given a phone with the app already installed, or will have the app installed on their existing phone if they already have one. At random times throughout the week, the app will ask participants to submit drug tests for opioids and cocaine, which participants will be able to do remotely without having to physically "go to" a testing site. For each test that demonstrates the participant hasn't used opioids or cocaine, the participant will be rewarded with money directly into a debit card. Participants will also be able to earn rewards for picking up treatment-related medications, attending onsite appointments, and other treatment-related activities.


Description:

This two-arm randomized trial will evaluate the impact of 48 weeks of the DynamiCare app-based CM (DCM) intervention on retention in methadone treatment and polysubstance use among 240 methadone maintenance (OTP) patients with comorbid opioid use disorder and cocaine use disorder. New enrollees in methadone maintenance at two community treatment programs will be randomly assigned to either methadone treatment-as-usual (TAU) at the OTP or methadone TAU paired with the DynamiCare Health app (TAU+DCM) including remote drug testing and monetary rewards for negative opioid and cocaine tests indicating abstinence. Data on methadone treatment retention will be obtained through OTP records, and follow-up assessments will be conducted at 3-, 6-, and 12-months post-enrollment. The study will examine participant outcomes in the domains of three aims: Aim 1: To determine the relative effectiveness of TAU+DCM compared to TAU alone in improving methadone treatment retention through 12-months post treatment entry. Aim 2: To determine the relative effectiveness of TAU+DCM compared to TAU alone in terms of [AIM 2a] reducing opioid use and cocaine use; and [Aim 2b] improving other secondary outcomes including non-targeted substance use and quality of life through 12-months post treatment entry. Aim 3: To explore app use patterns, acceptability, and perceived value of personalized content on opioid and polysubstance use through 12-months post treatment entry.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date September 29, 2027
Est. primary completion date June 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 or older 2. Cocaine use (self-reported in the past 30 days) 3. Willing and able to provide informed consent Exclusion Criteria: 1. Severe psychiatric disorders 2. On home detention 3. Visual impairment that would make the use of the phone app impractical 4. Living arrangement that currently restricts phone access

Study Design


Intervention

Behavioral:
DynamiCare Health
Participants earn incentives for: CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone). Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment.
Drug:
Methadone Treatment-As-Usual
Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.

Locations

Country Name City State
United States Friends Research Institute, Inc. Central Office Baltimore Maryland
United States Glenwood Life Counseling Center Baltimore Maryland
United States Institutes for Behavior Resources Baltimore Maryland
United States Friends Research Institute, Inc. Office Building Cerritos California

Sponsors (2)

Lead Sponsor Collaborator
Friends Research Institute, Inc. National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retention in Methadone Treatment through 48 Weeks The primary outcome of the proposed study is retention in methadone treatment, which will be determined via clinic attendance records, and will be defined as 7 days of continuous absence from scheduled clinic medication visits at any point during the 48-week intervention period. 48 weeks
Secondary Drug Use through 48 Weeks Self-reported data, clinical records, urinalysis at baseline and 3-/6-/12-month follow-ups, as well as random drug testing associated with the DynamiCare app will all be used in concert to determine opioid, cocaine, and other drug use during the 48-week intervention period. 48 weeks
Secondary Changes in Quality of Life through 48 Weeks Self-report data collected at baseline as well as at the 3-/6-/12-month follow-up assessments will assess changes in participants quality of life, including familial, legal, and/or medical issues, during the 48-week intervention period. 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04095624 - Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion N/A
Completed NCT04484610 - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study Phase 4
Recruiting NCT04598074 - Opioid Package Prototype (OPP) N/A
Recruiting NCT06033599 - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement Phase 3
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Completed NCT03570320 - Does Altering Narcotic Prescription Methods Affect Opioid Distribution Following Select Upper Extremity Surgeries? N/A
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Recruiting NCT05877157 - Pain AND Opioids After Surgery
Recruiting NCT06055205 - A Pain and Coordination Plan for Reduced Opioid Use After Accidental Injuries N/A
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT04868552 - Naloxone Education in Total Joint Patients N/A
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Terminated NCT06217380 - Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program N/A
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2
Not yet recruiting NCT03545516 - Wound Infiltration as Part of an Opioid Free Pain Management Pathway Following Cesarean Delivery Phase 2